Infection News

Copper oxide-containing surfaces significantly reduced Clostridioides difficile spores after 4 hours, according to study findings published in Infection Control & Hospital Epidemiology.

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients receiving immunosuppressive therapy.

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the company announced in a press release.

Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D, which is associated with an increased risk of liver-related complications and mortality, researchers found.

Splash pads have been linked to more than 10,000 cases of preventable waterborne illness caused by bacteria or viruses over a 26-year period, according to a CDC study.

Researchers found that removing Clostridioides difficile from gastrointestinal pathogen panels reduced unnecessary treatment without causing delays in diagnosis.

For November’s Clostridioides difficile Awareness Month, the Peggy Lillis Foundation has launched a “See C. diff diagnosed” campaign to educate the public on the most common health care-associated infection, according to a press release.

Each year, from Nov. 18 to Nov. 24, the CDC’s U.S. Antibiotic Awareness Week raises awareness about antimicrobial resistance and encourages the appropriate use of antibiotics and antifungals.

One person has died and 15 have been hospitalized in a multistate outbreak of Escherichia coli linked to consuming organic carrots, the CDC announced.